- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04075968
The Effect of Cognitive Group Exercise Combined With Physical Exercise in MS
February 6, 2021 updated by: Istanbul Physical Medicine Rehabilitation Training and Research Hospital
The Effect of Cognitive Group Exercise Combined With Physical Exercise in Multiple Sclerosis Patients
The aim of this study is to investigate the effect of cognitive rehabilitation in group with physical exercise in patients with Multiple Sclerosis.
We assume that cognitive therapy is an effective treatment for multiple sclerosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to investigate the effect of cognitive rehabilitation in group with physical exercise in patients with Multiple Sclerosis.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34500
- Health Sciences University Istanbul Physical Therapy and Rehabilitation Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with definitive Multiple Sclerosis between 20-65 years, with an Mini Mental State Test score less than 24, with an Extended Disability Status Scale score less than 4, trained for at least 5 years, have not received steroid therapy in the last 1 month
Description
Inclusion Criteria:
- Patients with an Mini Mental State Test score less than 24
- Patients with an Extended Disability Status Scale score less than 4
- Patients trained for at least 5 years
- Patients who have not received steroid therapy in the last 1 month
Exclusion Criteria:
- Patients who have not passed at least 3 months from the last Multiple Sclerosis attack
- Patients with hearing and vision problems that may interfere with communication
- The patients who Have other neurological and psychiatric disorder that will cause cognitive impairment
- Patients receiving medical treatment for spasticity, tremor, bladder disorder and fatigue
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
group 1
exercise group; 6 weeks, twice a week, 30 minutes physical group exercises and 30 minutes general cognitive function exercises will be applied as groups.
|
Cognitive exercise will be applied
|
|
group 2
control group; patients will be given physical and cognitive home exercise program individually.
|
Home exercise will be applied
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuro-psychometric Test (NPT)
Time Frame: 1 hour
|
It is a test that evaluates memory, working memory, planning, organization, attendance span.Evaluation is made according to the number of items filled.
The higher number items filled indicates the better status
|
1 hour
|
|
Berg Balance Scale
Time Frame: 15 minutes
|
It is a scale which consists of 14 items.
Each item is scored on a five-point scale (0-4).The maximum score for this assessment is 56 and the minimum score for this assessment is 0. Scores below 45 indicate balance impairment.
The higher point indicates the better status
|
15 minutes
|
|
Mini Mental State Test (MMST)
Time Frame: 10-15 minutes
|
It is a test that evaluates different subset of cognitive status including attention, memory, language, orientation, visuospatial proficiency.
It is scored on a scale of 0-30 with scores.
Scores above 25 are interpreted as normal cognitive status.
|
10-15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Ashworth Scale (MAS)
Time Frame: 3 minutes
|
The MAS is a 6-point rating scale which assesses muscle tone by manually manipulating the joint through its available range of motion and clinically recording the resistance to passive movements.
The lower point indicates the better status
|
3 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Arzu Esmeray, IstanbulPMHTRH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2018
Primary Completion (ACTUAL)
November 15, 2019
Study Completion (ACTUAL)
December 1, 2019
Study Registration Dates
First Submitted
August 11, 2019
First Submitted That Met QC Criteria
August 29, 2019
First Posted (ACTUAL)
September 3, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 6, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IstanbulPMRTRH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cognitive exercise
-
Nova Scotia Health AuthorityTerminatedChronic Phase Stroke PatientsCanada
-
Sunnybrook Health Sciences CentreFondazione Italiana Sclerosi Multipla; University of Alabama at Birmingham; University... and other collaboratorsCompletedCognitive Impairment | Multiple Sclerosis, Primary ProgressiveCanada
-
The Hong Kong Polytechnic UniversityUniversity of Santo TomasUnknownMild Cognitive ImpairmentPhilippines
-
University of SalamancaNot yet recruitingAging | Cognitive Abilities | Mobility and Independence | Well-being/Quality of Life | Institutionalized Older Adults
-
Colorado State UniversityUniversity of Colorado, Denver; National Institute of Diabetes and Digestive...RecruitingDepressive Disorder | Depression | Glucose Metabolism Disorders | Mood Disorders | Insulin Resistance | Hyperinsulinism | Metabolic Disease | Mental Disorder in AdolescenceUnited States
-
University of Alabama at BirminghamPulmonary Fibrosis FoundationCompletedIdiopathic Pulmonary FibrosisUnited States
-
Parc de Salut MarCompleted
-
Chiang Mai UniversityCompleted
-
Marquette UniversityRecruitingPain | Physical Activity | Fibromyalgia | Exercise | Autonomic DysfunctionUnited States